Mina Therapeutics, of London, presented preclinical data on its MTL-CEBPA program in which the compound was shown to improve several markers of liver function in a rat model of liver failure. MTL-CEBPA is the first development candidate to emerge from Mina's RNA activation platform and the company is advancing the compound into clinical investigation in 2016 with an initial focus on patients with liver cancer and impaired liver function.